KRAS and non-small cell lung carcinoma: Despite coordinated efforts [1], anti-KRAS drug discovery lags behind other oncogene targets [3], and only one single KRASG12C inhibitor (sotorasib) was recently approved by the FDA for non-small-cell lung cancer (NSCLC) [10,11].